Evelo Biosciences, Inc. (EVLO): Price and Financial Metrics
GET POWR RATINGS... FREE!
EVLO Stock Price Chart Interactive Chart >
EVLO Price/Volume Stats
| Current price | $0.25 | 52-week high | $4.36 |
| Prev. close | $0.26 | 52-week low | $0.24 |
| Day low | $0.24 | Volume | 162,955 |
| Day high | $0.28 | Avg. volume | 165,289 |
| 50-day MA | $0.83 | Dividend yield | N/A |
| 200-day MA | $1.80 | Market Cap | 27.00M |
Evelo Biosciences, Inc. (EVLO) Company Bio
Evelo Biosciences, Inc. focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn’s colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is based in Cambridge, Massachusetts.
Latest EVLO News From Around the Web
Below are the latest news stories about EVELO BIOSCIENCES INC that investors may wish to consider to help them evaluate EVLO as an investment opportunity.
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsCAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today reported financial results and business highlights for the fourth quarter and full year 2022. “We continued to progress on our SINTAX platform and our clinical pipeline in 2022. We look forward to important cl |
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis, SINTAX, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 16, 2023 to report its fourth quarter and full year 2022 financial results and business highlights. To listen to the conference call by ph |
After Plunging -40.39% in 4 Weeks, Here's Why the Trend Might Reverse for Evelo Biosciences, Inc. (EVLO)Evelo Biosciences, Inc. (EVLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care ConferenceCAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, today announced that Mark Plinio, J.D., Chief Commercial Officer will participate in a dermatology panel at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET. A live audio webcast of the panel will be available |
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns – – Dosing in EDP2939 Phase 2 trial in patients with moderate psoriasis has been initiated – – EDP2939 Phase 2 data in psoriasis anticipated in 2H 2023 – CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intesti |
EVLO Price Returns
| 1-mo | -69.66% |
| 3-mo | -82.88% |
| 6-mo | -87.56% |
| 1-year | -93.13% |
| 3-year | -92.69% |
| 5-year | N/A |
| YTD | -84.47% |
| 2022 | -73.48% |
| 2021 | -49.79% |
| 2020 | 197.78% |
| 2019 | -68.79% |
| 2018 | N/A |
Loading social stream, please wait...